HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $27
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Robert Burns maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $26 to $27.
HC Wainwright & Co. analyst Robert Burns maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $26 to $27.